Tag : HEAD-TO-HEAD TRIAL

CONFERENCE UPDATE

Omalizumab outperforms oral immunotherapy in multi-food allergy treatment
Food allergy is a common condition that significantly impacts patients' quality of life and carries the risk of life-threatening anaphylaxis. Until recently, treatment options were largely limited to lifelong allergen avoidance. However, two Food and Drug Administration (FDA)-approved therapies